Related Experiment Videos

Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics

C M Galmarini1, K Kamath, A Vanier-Viornery

  • 1INSERM 590-Laboratoire de Cytologie Analytique, Faculté de Médécine Rockefeller, Lyon 69373, France. fgalma@rockefeller.univ-lyon1.fr

Insights

Mutant p53 (mut-p53) breast cancer cells show resistance to microtubule drugs due to altered microtubule dynamics and composition. Wild-type p53 (wt-p53) cells are more sensitive.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Biochemistry

Background:

  • The p53 protein is a critical tumor suppressor involved in cell cycle regulation and apoptosis.
  • Microtubules are essential components of the cytoskeleton, playing key roles in cell division and intracellular transport.
  • Drug resistance in cancer, particularly to microtubule-targeting agents, remains a significant clinical challenge.

Purpose of the Study:

  • To investigate the impact of wild-type p53 (wt-p53) versus mutant p53 (mut-p53) on microtubule dynamics and composition.
  • To compare the sensitivity of wt-p53 and mut-p53 breast cancer cells to microtubule-targeted drugs.

Main Methods:

  • Utilized MCF-7 human breast adenocarcinoma cell lines expressing either wt-p53 or mut-p53.
  • Employed high-resolution time-lapse fluorescence microscopy to analyze microtubule dynamics in living cells.
  • Assessed protein levels of various tubulin isotypes and associated proteins using biochemical methods.

Main Results:

  • Mut-p53 cells exhibited significant resistance to vinca alkaloids and taxanes compared to wt-p53 cells.
  • Microtubule dynamics were significantly increased in mut-p53 cells, characterized by increased growing/shortening phases and catastrophe frequency.
  • Mut-p53 cells showed altered protein expression, including increased tubulin polymerization, class IV beta-tubulin, STOP, and survivin, with decreased class II beta-tubulin, MAP4, and FHIT.

Conclusions:

  • p53 protein plays a role in regulating microtubule composition and function.
  • Altered p53 function can lead to complex microtubule-associated mechanisms conferring resistance to tubulin-binding agents.
  • These findings suggest novel therapeutic strategies targeting microtubule dynamics in p53-mutated cancers.

Related Concept Videos